Medifast Announces First Quarter 2026 Financial Results
Medifast reported Q1 2026 revenue of $76.0 million, down 34.3% year-over-year, with a net loss of $0.19 per share compared to a $0.07 loss in the prior year. The decline was driven by a 44.9% drop in active earning coaches to 14,000, attributed to client acquisition challenges and competition from GLP-1 weight-loss medications.
Key figures
- Guidance
- Q2 2026 revenue $60M-$80M, loss per share $0.50-$1.00; FY 2026 revenue $270M-$300M, loss per share $1.55-$2.75
- Revenue Yoy
- -34.3%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.